Estimation of the relative potency of two glycine antagonists on NMDA-induced depolarizations in BRSC and ARCS.
Corsi
M
M
Pharmacology Research Department, GlaxoWellcome S.p.A., Verona, Italy.
Bettelini
L
L
Fina
P
P
Trist
D G
DG
D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D007608:Kainic Acid / Q000494:pharmacology; D007736:Kynurenic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D016202:N-Methylaspartate / Q000494:pharmacology*; D011189:Potassium Chloride / Q000494:pharmacology; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D013116:Spinal Cord / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects*
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D016194:Receptors, N-Methyl-D-Aspartate; C092062:licostinel; D016202:N-Methylaspartate; D011189:Potassium Chloride; D007736:Kynurenic Acid; C057013:7-chlorokynurenic acid; D007608:Kainic Acid